Investor Resource Book

February 2022

FOR INVESTOR USE ONLY; NOT FOR PROMOTIONAL USE.

Gilead's Mission

To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

Our Ambitions

Bring 10+ transformative

Be the biotech

Deliver shareholder

therapies to patients

employer and partner

value in a sustainable,

by 2030

of choice

responsible manner

Welcome to our Gilead Investor Resource Book. This book is a collection of materials intended to streamline the reader's initial review of Gilead materials. Of course, there is no substitute for our SEC filings, and our most recent disclosures may be found on our Investor Relations page at http://investors.gilead.com. As a supplement, however, we have pulled together materials designed to help you get up to speed on Gilead's products, strategy, team and performance to date. Any financial data included is available in Microsoft Excel, on request.

As you get to know Gilead, please reach out to the Investor Relations team if you have questions or feedback. In the meantime, and on behalf of the management team, thank you for your interest in Gilead.

Jacquie Ross, CFA

Vice President, Investor Relations

Email: investor_relations@gilead.com

3

Investor Resource Book

Contents

  1. About Gilead
  2. Our Business
  3. Building a Sustainable and Diversified Gilead
  4. Our Therapeutic Areas of Focus
  5. Virology

17 Oncology

28 Inflammation

  1. Key Corporate Transactions and Partnerships
  2. Corporate Responsibility
  3. Our People
  4. Access to Our Medicines Around the World
  5. Role of Veklury (Remdesivir) in the COVID‑19 Pandemic
  6. Press Releases: Corporate & Earnings
  7. Press Releases: Data Updates
  8. Our Leadership Team
  1. Overview of the Board of Directors
  2. Our Board of Directors
  1. Analyst Coverage and Largest Investors
  2. Capital Allocation Balances Investment and Shareholder Return
  3. Debt and Credit Facilities
  4. Financials FAQ
  5. Financials

4

Investor Resource Book

About Gilead

Gilead was founded in 1987 as a biopharmaceutical company focused on viral diseases, cardiovascular disease and cancer. The company was named after a Middle Eastern medication known as the balm of Gilead, which founder Michael Riordan considered the world's first pharmaceutical product.

By 2001, Gilead received its first HIV therapy approval and decided to focus on virology. Following the acquisition of Triangle Pharmaceuticals in 2003, the combination of emtricitabine with internally developed clinical candidates ultimately delivered many firsts in HIV. Additional milestones in virology included the development of treatments for chronic viral hepatitis B, the first single tablet regimen for HIV and a transformational cure for HCV.

Leadership in HIV and HCV fueled growth from 2012 to 2015. While growth in HIV has continued since then, the sharp decline in HCV revenue associated with the curative nature of our HCV treatment (resulting in fewer new patients) as well as generics and competitive products have masked that growth.

Today, Gilead continues to innovate in virology, and notably HIV, where we believe the right long-acting regimens could continue our leadership in HIV treatment and catalyze the prevention market. Additionally, the company has been an active acquirer and partner in recent years, with the goal of building a diversified portfolio extending beyond virology, and into oncology and inflammation. The assets added over the last few years are varied across indications, mechanism of action and clinical stage.

In summary, Gilead is a company in the midst of transformation, building on our established track record in HIV and HCV, and extending into a more diversified and impactful portfolio to reach more patients across virology, oncology and inflammation.

5

1987 Gilead is founded

1992 Gilead completes its IPO

1996 John Martin appointed CEO

Focus on

Virology

2012

Gilead acquires Pharmasset, adding three clinical stage HCV candidates

2013

Sovaldi, first HCV cure in tablet form, approved by FDA

2016 John Milligan appointed CEO

Building a

Diversified

Portfolio

2001

Viread for HIV approved by FDA

2003

Gilead acquires Triangle Pharmaceuticals, adding emtricitabine to HIV portfolio

2006

Atripla, first single tablet regimen for HIV, approved by FDA

Leadership in

HIV and HCV

2017

Gilead acquires Kite, adding cell therapy: Yescarta approved by FDA

2018

Biktarvy, market leading daily pill regimen for HIV, approved by FDA

2019

Daniel O'Day appointed Chairman and CEO

2020

Gilead acquires Immunomedics

  • Forty Seven to strengthen oncology pipeline

2021

Trodelvy receives full FDA approval for 2L mTNBC

Investor Resource Book

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Gilead Sciences Inc. published this content on 12 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 February 2022 00:31:03 UTC.